Abstract Library

#3912 Development of a mobile app for patients with neuroendocrine neoplasms: A collaborative project between United Kingdom NET Society and Neuroendocrine Tumour Patient Foundation

Introduction: Digital technology has an important role in the management of long term conditions.

Conference:

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Alaghband N, Ramage J, Solis B, Virk J,

Keywords: PROMs, Mobile Health, Neuroendocrine Tumor, Charity, patient focussed, bespoke, QoL,

#3861 Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis

Introduction: The incidence of type I gastric neuroendocrine neoplasms (gNEN) has increased substantially over the past 50 years, although studies evaluating the association with chronic autoimmune atrophic gastritis (CAAG) in the long term have been inconsistent.

Conference:

Presenting Author: Gallo C

Authors: Gallo C, Laffusa A, Elvevi A, Mass S,

Keywords: atrophic gastritis, autoimmune gastritis, gastrin, neuroendocrine tumor,

#3632 Medullary thyroid carcinoma and somatostatin analogues, a possible therapeutic choice in asymptomatic and slow radiological progression metastatic recurrent disease after surgery – Case report of a 22-years long term survival patient

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor of the thyroid and accounts for 1%-2% of thyroid cancers in the United States. MTCs present with locoregional metastasis in 50% of patients and distant metastasis in 10%-15% at diagnosis. Treatment options for recurrent or progressive disease according to RECIST 1.1 criteria, are limited. Tyrosine kinase-inhibitors (TKI) are preferred as first-line systemic therapy. Although somatostatin analogues (SSA) may play a role in MTC, limited evidence is available.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Maratta M, Giampietro A, de Marinis L,

Keywords: medullary thyroid carcinoma (MTC), somatostatin analogues, survival,

#3626 Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy

Introduction: PRRT has shown favourable results in NETs. Long-term safety and efficacy data for 177Lu-Octreotate PRRT, particularly in combination with chemotherapy, is lacking.

Conference:

Presenting Author: Ransom D

Authors: Ransom D, Kennedy K, Turner J, Macdonald W, Boardman G,

Keywords: PRRT, long term, chemotherapy, leukaemia, myelodysplasia, renal,

#3535 A case series and literature review of DIPNECH

Introduction: DIPNECH is characterised by bilateral carcinoids ≤0.5cm, tumorlets

Conference:

Presenting Author:

Authors: Montebello A, Ricketts W, Druce M,

Keywords: DIPNECH, clinical presentation, diagnosis, longitudinal behaviour,